Merck KGaA (FRA:MRK) has been assigned a €95.00 ($113.10) price objective by investment analysts at Bank of America in a report issued on Wednesday. The brokerage presently has a “neutral” rating on the healthcare company’s stock. Bank of America’s target price would suggest a potential upside of 6.91% from the stock’s previous close.

Several other equities analysts also recently issued reports on the company. UBS set a €120.00 ($142.86) target price on Merck KGaA and gave the company a “buy” rating in a research report on Monday, October 23rd. equinet set a €112.00 ($133.33) target price on Merck KGaA and gave the company a “buy” rating in a research report on Thursday, August 31st. Societe Generale set a €103.00 ($122.62) target price on Merck KGaA and gave the company a “neutral” rating in a research report on Tuesday, September 5th. Goldman Sachs Group set a €105.00 ($125.00) target price on Merck KGaA and gave the company a “neutral” rating in a research report on Wednesday, September 6th. Finally, Independent Research set a €105.00 ($125.00) target price on Merck KGaA and gave the company a “neutral” rating in a research report on Monday, August 28th. Twelve analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of €107.81 ($128.34).

Shares of Merck KGaA (FRA:MRK) opened at €88.86 ($105.79) on Wednesday. Merck KGaA has a twelve month low of €87.33 ($103.96) and a twelve month high of €115.00 ($136.90).

TRADEMARK VIOLATION NOTICE: “Merck KGaA (MRK) Given a €95.00 Price Target by Bank of America Analysts” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://www.americanbankingnews.com/2017/12/10/merck-kgaa-mrk-given-a-95-00-price-target-by-bank-of-america-analysts.html.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.